Amphotericin B-metronidazole combination against Candida spp

Revista Iberoamericana de Micologia

Volumn 15, Issue 2, 1998, Pages 78-80

  Chang, Marilene Rodrigues ^a,b   Cury, Arlete Emily ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Amphotericin B; Candida spp; Combined therapy; Drug synergism; Metronidazole

Indexed keywords

EID: 2742533703     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Lacaz CS, Porto A, Martins ECM. Micologia médica: fungos, actinomicetos e algas de interesse médico. São Paulo, Sarvier, 1991: 695.
2. Mills W, Chopra R, Linch DC, et al. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single - center experience of 133 episodes in 116 patients Br J Haematol 1994; 86:754-760
3. Kobayashi GS, Medoff F Measurement of activity of fungal drugs. In: Howard DH (Ed), Fungi pathogenic for humans and animals New York, Marcel Dekker. 1983;3:375-371.
4. Mitsutake K, Kohnos S, Miyazaky Y et al. In vitro and in vivo antifungal activities of liposomal amphotericin B and amphotericin B lipid complex. Mycopathologia 1994, 128:13-17.
5. Brajtburg, J, Kobayashi D, Medoff G, Kobayashi GS. Antifungal action of amphotericin B in combination with other polyene or imidazole antibiotics. J Infect Dis 1982;146:133-146.
6. Odds FC. Candida and candidosis (2 ed). London. Ballière Tindall, 1988: 468p.
7. Karyotakis NC, Anaissie EJ, Manchem R, et al. Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice. J Infect Dis 1993;168:1311-1313.
8. Petrou MA, Rogers TR. Interactions in vitro between polyenes and imidazoles against yeasts J Antimicrob Chemother 1991; 27:491-506
9. Shadomy S, Wagner G, Espinel-Ingroff A. In vitro studies with combinations of 5-flurocytosine and amphotericin B. Antimicrob Agents Chemother, 1975; 8:117-121
10. Van Der Auwera P. Synergistic, additive, and antagonistic activity of antimicrobial agents: How to measure? What are the clinical consequences? Applications to the new fluoroquinolones. Infect Dis Newslett 1992; 11:49-56.
11. Ghannoum MA, Fu Y, Ibrahim AS, Mortar LA, et al In vitro determination of optimal antifungal combination against Cryptococcus neoformans. Antimicrob Agents Chemother 1935; 39:2459-2465.
12. Odds FC. Interactions among amphotericin B, 5 fluorocytosine, ketoconazole and miconazole against pathogenic fungi in vitro. Antimicrob Agents Chemother 1982; 22:763-770.
13. Cury AE Interaçōes de associaçāo da Anfotericina B com fármacos azóicos e halocetamidas contra isolados de Candida albicans e Candida tropicalis. São Paulo, 1994 121p. (Livre-docência thesis -Faculdade de Ciências Farmacêuticas, USP).
14. Sugar AM. Use of amphotericin B with azole antifungal drugs; what are we doing? Antimicrob Agents Chemother 1995; 39:1907-1912
15. Chmel H, Louria DB. Antifungal antibiotics: mechanism of action, resistance, susceptibility testing, and assays of activity in biological fluids. In. Lorian V (Ed) Antibiotics in laboratory medicine. Baltimore, Willians & Wilkins, 1980: 170-192.
16. Berenbaum MCA method for testing for synergy with any number of agents. J Infect Dis 1978;137:122-130.
17. Shadomy S, Espinel-Ingroff A, Cart WR. Laboratory studies with antifungal agents: susceptibility tests and bioassays. In: Lennette EH, Ballows A, Hausler WJ et al. (Eds). Manual of clinical microbiology (4. Ed). Washington, American Society for Microbiology 1985: 991-999.
18. Scalarone GM, Mikami Y, Kurita N. Comparative studies on the postantifungal effect produced by the synergistic interaction of flucytosine and amphothericin B on C. albicans. Mycopathologia 1992;120:133-138.
19. Brogden RN, Heel RC, Speight TM, Avery GS Metronidazole in anaerobic infections: a review of its activity, pharmacokinetics and therapeutic use. Drugs 1978;16:387-417.
20. Korolkovas A. Essentials of medicinal chemistry (2 Ed). New York, Wiley-Interscience 1988: 658-661